ONCE - Spark Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
78.39
-0.63 (-0.80%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close79.02
Open79.04
Bid74.50 x 2200
Ask84.00 x 900
Day's Range76.62 - 79.04
52 Week Range41.06 - 91.75
Volume270,476
Avg. Volume614,112
Market Cap2.931B
Beta2.84
PE Ratio (TTM)N/A
EPS (TTM)-7.62
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est78.76
Trade prices are not sourced from all markets
  • Which Is the Best Hemophilia Stock to Buy Now?
    Motley Foolyesterday

    Which Is the Best Hemophilia Stock to Buy Now?

    New drugs to treat the rare bleeding disorder are on the way, but which drugmaker will come out ahead?

  • ACCESSWIRE3 days ago

    Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / May 25, 2018 / If you want a free Stock Review on SRNE sign up now at www.wallstequities.com/registration. On Thursday, May 24, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Sierra Oncology Inc. (NASDAQ: SRRA), Sorrento Therapeutics Inc. (NASDAQ: SRNE), Spark Therapeutics Inc. (NASDAQ: ONCE), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI).

  • ACCESSWIRE4 days ago

    Wired News - Spark Therapeutics and Pfizer Announced Positive Data from Phase-1/2 Clinical Trial of SPK-9001 for Haemophilia B Treatment

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Spark Therapeutics, Inc. (NASDAQ: ONCE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ONCE as the Company's latest news hit the wire. On May 22, 2018, Spark Therapeutics and Pfizer Inc. announced that it has presented encouraging results from ongoing Phase-1/2 clinical trial assessing investigational SPK-9001 for severe or moderately severe hemophilia B, at the World Federation of Hemophilia (WFH) World Congress in Glasgow, Scotland. All 15 participants in the clinical trial followed for 5 to 121 weeks had discontinued routine infusions of factor IX concentrates.

  • Spark, Pfizer report progress on gene therapy for hemophilia
    American City Business Journals5 days ago

    Spark, Pfizer report progress on gene therapy for hemophilia

    The clinical testing program is expected to transition to Pfizer from Spark Therapeutics this summer.

  • GlobeNewswire6 days ago

    Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events

    Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (PFE), today announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe (FIX:C

  • GlobeNewswire6 days ago

    Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events

    Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (PFE), today announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe (FIX:C ≤ 2 percent) hemophilia B, had discontinued routine infusions of factor IX concentrates. None of the 15 participants experienced serious adverse events, and there were no thrombotic events or factor IX inhibitors, as of the May 7, 2018 data cutoff.

  • High Growth AMEX Stocks For The Day
    Simply Wall St.15 days ago

    High Growth AMEX Stocks For The Day

    Companies such as UQM Technologies and Spark Therapeutics have a significantly positive future outlook on the basis of their profitability and returns. Investors seeking to enhance their portfolio should considerRead More...

  • Recent Developments, Recommendations for JAZZ in May
    Market Realist17 days ago

    Recent Developments, Recommendations for JAZZ in May

    In May, Jazz Pharmaceuticals (JAZZ) submitted a supplemental new drug application (or sNDA) to the FDA for the label expansion of Xyrem for the inclusion of its use in the treatment of cataplexy and EDS (excessive daytime sleepiness) in pediatric patients with narcolepsy. In April, Jazz Pharmaceuticals entered into an agreement with Spark Therapeutics (ONCE) whereby Jazz would purchase a rare pediatric disease priority review voucher for $110 million that would allow it to accelerate the FDA review process for one of its future regulatory submissions. Of the 23 analysts tracking Jazz Pharmaceuticals in May, six have recommended “strong buys” on the stock, while 13 have recommended “buys.” Four analysts have recommended “holds” on Jazz Pharmaceuticals in May.

  • Thomson Reuters StreetEvents19 days ago

    Edited Transcript of ONCE earnings conference call or presentation 8-May-18 12:30pm GMT

    Q1 2018 Spark Therapeutics Inc Earnings Call

  • Associated Press19 days ago

    Spark Therapeutics: 1Q Earnings Snapshot

    The Philadelphia-based company said it had a loss of $1.25 per share. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a ...

  • GlobeNewswire20 days ago

    Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress

    PHILADELPHIA, May 08, 2018-- Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for ...

  • Why Hemophilia Patients Could Pay $1.5 Million For Gene Therapy
    Investor's Business Daily20 days ago

    Why Hemophilia Patients Could Pay $1.5 Million For Gene Therapy

    BioMarin, Spark and UniQure are duking it out for share in hemophilia gene therapies — a market that could generate north of $1.5 million per patient.

  • CNBC20 days ago

    First US drug priced at more than $1 million may be on the horizon

    New gene therapies that aim to cure hemophilia, a disease affecting the blood's ability to clot, are on the horizon. Treating hemophilia is costly. In the paradoxical world of drug pricing, the first U.S. price tag exceeding $1 million for a medicine is being contemplated as the nation's agita over the cost of prescription drugs climbs ever higher.

  • GlobeNewswire27 days ago

    Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights

    Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 8, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the first quarter that ended March 31, 2018, and recent business highlights. At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease.

  • GlobeNewswire27 days ago

    Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Brake Technologies, and Resource Capital — What Drives Growth in Today's Competitive Landscape

    NEW YORK, May 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Vitamin ...

  • GlobeNewswire27 days ago

    Spark Therapeutics to Host Conference Call on Tuesday, May 8 at 8:30 a.m. ET to Discuss First Quarter Results and Recent Business Highlights

    Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, May 8, 2018, at 8:30 a.m. ET to discuss corporate and financial results for the first quarter that ended March 31, 2018, and recent business highlights. At Spark Therapeutics, a fully integrated company committed to discovering, developing and delivering gene therapies, we challenge the inevitability of genetic diseases, including blindness, hemophilia and neurodegenerative diseases. We have successfully applied our technology in the first FDA-approved gene therapy in the U.S. for a genetic disease, and currently have three programs in clinical trials, including product candidates that have shown promising early results in patients with hemophilia. At Spark, we see the path to a world where no life is limited by genetic disease.

  • Peninsula drug maker swings $110 million deal for voucher
    American City Business Journals27 days ago

    Peninsula drug maker swings $110 million deal for voucher

    The FDA issues priority review vouchers to companies that receive approval for rare pediatric diseases. Spark Therapeutics is selling its voucher to Jazz Pharmaceuticals.

  • Voucher sale brings $110M payday for Spark Therapeutics
    American City Business Journals27 days ago

    Voucher sale brings $110M payday for Spark Therapeutics

    The FDA issues priority review vouchers to companies that receive approval for rare pediatric diseases. Spark Therapeutics is selling its voucher to Jazz Pharmaceuticals.

  • GlobeNewswire28 days ago

    Spark Therapeutics Sells Priority Review Voucher for $110 Million

    PHILADELPHIA, April 30, 2018-- Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced it has entered into an agreement ...

  • Analysts’ Ratings for Sarepta Therapeutics and Peers in April
    Market Realistlast month

    Analysts’ Ratings for Sarepta Therapeutics and Peers in April

    How Is Sarepta Therapeutics Positioned in 2018? Sarepta Therapeutics (SRPT) is a commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics, gene therapy, and other genetic approaches for treating rare neuromuscular diseases. Of the 19 analysts covering Sarepta Therapeutics in April 2018, six analysts gave the stock a “strong buy” rating, 11 analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.

  • Investopedialast month

    A Winning Stock Picker's 8 Favorite Plays

    A fund manager who's up 10% so far this year shares his top picks.

  • Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitals
    American City Business Journalslast month

    Spark Therapeutics' ground-breaking gene therapy now being administered at select hospitals

    Spark's first product, Luxturna, was approved by the FDA in December to treat an inherited retinal disorder that leads to blindness if untreated. The first patients have been treated with the gene therapy, which is now available at a select group of medical centers.

  • Novartis (NVS) Beats Earnings and Revenue Estimates in Q1
    Zackslast month

    Novartis (NVS) Beats Earnings and Revenue Estimates in Q1

    Novartis reported encouraging results for the first quarter as sales and earnings both topped expectations on Cosentyx and Entresto strength.

  • How Analysts View Tetraphase Pharmaceuticals in April 2018
    Market Realistlast month

    How Analysts View Tetraphase Pharmaceuticals in April 2018

    Tetraphase Pharmaceuticals (TTPH) is a clinical-stage biopharmaceutical company focused on creating novel antibiotics. These antibiotics treat serious and life-threatening multidrug-resistant infections by using the company’s proprietary chemistry technology. Its lead product candidate is eravacycline, which is being developed as an intravenous antibiotic.

  • Exploring Spark Therapeutics’ Cash Flows
    Market Realistlast month

    Exploring Spark Therapeutics’ Cash Flows

    Spark Therapeutics (ONCE) spent $154.5 million on operating activities in 2017 compared to $80.4 million in 2016. This spending consisted of a net loss of $253.5 million, a depreciation and amortization expense of $4.9 million, and a stock-based compensation expense of $41.4 million.